Health Catalyst, Inc. (NASDAQ:HCAT) Insider Sells $11,161.32 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT) insider Linda Llewelyn sold 1,324 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $8.43, for a total transaction of $11,161.32. Following the transaction, the insider now directly owns 115,599 shares of the company’s stock, valued at $974,499.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Linda Llewelyn also recently made the following trade(s):

• On Thursday, August 15th, Linda Llewelyn sold 1,328 shares of Health Catalyst stock. The shares were sold at an average price of $6.57, for a total transaction of $8,724.96.
• On Monday, July 15th, Linda Llewelyn sold 1,290 shares of Health Catalyst stock. The stock was sold at an average price of $6.51, for a total value of $8,397.90.

Health Catalyst Price Performance

Shares of HCAT stock opened at $8.69 on Friday. Health Catalyst, Inc. has a one year low of $5.42 and a one year high of $11.41. The company’s fifty day moving average price is $7.29 and its 200-day moving average price is $6.92. The company has a market capitalization of $513.01 million, a price-to-earnings ratio of -4.70 and a beta of 1.31.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.04. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The business had revenue of $75.90 million during the quarter, compared to analyst estimates of $74.96 million. During the same quarter in the prior year, the business posted ($0.21) EPS. Health Catalyst’s revenue for the quarter was up 3.7% compared to the same quarter last year. Equities research analysts expect that Health Catalyst, Inc. will post -0.35 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on HCAT. JPMorgan Chase & Co. upped their price objective on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Piper Sandler lowered their price objective on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 26th. Evercore ISI dropped their price objective on shares of Health Catalyst from $9.00 to $8.00 and set an “outperform” rating on the stock in a report on Tuesday, July 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a report on Friday. Finally, Stephens dropped their price target on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 8th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.42.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Primecap Management Co. CA raised its position in shares of Health Catalyst by 26.7% during the fourth quarter. Primecap Management Co. CA now owns 1,419,577 shares of the company’s stock valued at $13,145,000 after buying an additional 299,139 shares during the last quarter. Kennedy Capital Management LLC bought a new stake in Health Catalyst in the 1st quarter valued at $8,780,000. ClariVest Asset Management LLC lifted its stake in Health Catalyst by 303.9% in the 1st quarter. ClariVest Asset Management LLC now owns 282,325 shares of the company’s stock worth $2,126,000 after purchasing an additional 212,425 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Health Catalyst by 38.3% during the 1st quarter. Acadian Asset Management LLC now owns 724,560 shares of the company’s stock valued at $5,453,000 after purchasing an additional 200,494 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of Health Catalyst during the 1st quarter valued at about $1,079,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.